Celebrex Total Knee Arthroplasty Study
| Status: | Terminated |
|---|---|
| Conditions: | Arthritis, Chronic Pain, Osteoarthritis (OA) |
| Therapuetic Areas: | Musculoskeletal, Rheumatology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 12/6/2018 |
| Start Date: | November 2006 |
| End Date: | July 2007 |
Multicenter, Double Blind, Randomized, Placebo Controlled Trial Of The Efficacy And Safety Of Usual Care Plus Celecoxib Compared To Placebo For Peri-Operative And Rehabilitation Pain Control And Return To Function In Osteoarthritis Patients Undergoing Total Knee Arthroplasty
This study will investigate the benefits of administering celecoxib (Celebrex), a selective
cyclooxygenase -2 (COX-2) inhibitor, in treating osteoarthritis (OA) subjects undergoing
elective unilateral primary total knee arthroplasty (TKA) from the pre-operative phase to the
management of post total knee replacement pain, and through the 6 weeks of physical therapy
and rehabilitation.
cyclooxygenase -2 (COX-2) inhibitor, in treating osteoarthritis (OA) subjects undergoing
elective unilateral primary total knee arthroplasty (TKA) from the pre-operative phase to the
management of post total knee replacement pain, and through the 6 weeks of physical therapy
and rehabilitation.
Inclusion Criteria:
- The subject is a male or female 18 years or older with osteoarthritis of the knee
scheduled to undergo elective unilateral primary total knee arthroplasty because of
OA, performed under a standardized regimen of anesthesia and procedure.
Exclusion Criteria:
- Subject has a history of inflammatory arthritis (e.g. rheumatoid arthritis, ankylosing
spondylitis) other than osteoarthritis.
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials